Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone, GHRH(1-44). It belongs to the secretagogue class of research peptides — compounds that act upstream of the pituitary to stimulate the endogenous release of growth hormone (GH), rather than supplying GH directly. That upstream position makes it a useful tool for studying the physiology of the GH/IGF-1 axis in a way that preserves normal feedback regulation in model systems.
Secretagogue Mechanism
Tesamorelin binds the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and release. Because it engages the receptor for endogenous GHRH, its GH-releasing activity in research models remains subject to the normal regulatory brakes of the axis, including somatostatin tone and IGF-1 feedback — a contrast with direct GH administration.
Structural Stabilization
Native GHRH is rapidly degraded, primarily by dipeptidyl peptidase-4 (DPP-4). Tesamorelin carries an N-terminal trans-3-hexenoyl modification that confers resistance to this degradation, extending its stability relative to native GHRH. It is a common reference compound in structure-stability studies of GHRH-family peptides.
Research Applications
- GH/IGF-1 axis physiology and feedback-regulation models
- Somatotroph signaling and GHRH-receptor pharmacology
- Comparative secretagogue studies (GHRH analogs vs ghrelin-receptor agonists)
- DPP-4 resistance and peptide-stabilization research
- Bone and connective-tissue repair models within the GH axis
References
- Ferdinandi ES, Brazeau P, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol 2007. PMID: 17214611.
This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.